Company: BLNE
Filing Date: 2025-11-14
Form Type: 424B3
Source: 0001493152-25-023493
Chunk: 10

Company: Beeline Holdings, Inc.
Filing Date: 2025-11-14
Form: 424B3
Chunk 10
---
 the conditions set forth in the Purchase Agreement. We also issued to C/M 573,925 shares of Series G Convertible Preferred Stock as commitment shares pursuant to the Purchase Agreement, which as adjusted are convertible into up to 175,271 shares of common stock at C/M’s election, subject to beneficial ownership limitations. The total of 5,175,271 shares of common stock issuable under the Purchase Agreement and pursuant to the Series G issued thereunder, would represent approximately 19% of total number of shares of our common stock outstanding as of November 10, 2025. See also “Capitalization” beginning on page 14.

C/M may ultimately purchase all, some or none of the shares of our common stock that may be sold pursuant to the Purchase Agreement in connection with our rights to direct C/M’s purchases at our discretion and, after it has acquired shares, C/M may sell all, some or none of those shares. Therefore, sales to C/M by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock to C/M, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.

| 7 |

Further, certain of our outstanding derivatives securities, including convertible preferred stock and warrants, contain anti-dilution price protection provisions which provide for adjustments to conversion and exercise prices, and an increase in the shares underlying such securities, if we sell shares at a per share price below the applicable conversion or exercise price. Therefore, if we issue shares at prices that are lower than these conversion and exercise prices, these conversion prices will automatically be lowered to the new lower sale price. This would cause additional dilution to our common stockholders and result in our receiving less cash upon exercise of warrants. Additionally, because the Company hopes to avoid such an outcome, our ability to raise capital under the ELOC will be limited to the extent our common stock trades near or below these prices.

By virtue of the terms of the Purchase Agreement, it is not possible to predict the number of shares we will sell nor the prices at which we will sell the shares under the Purchase Agreement, nor the consequences (including dilution to existing stockholders) which may result therefrom.

We may not be able to access sufficient funds under the Purchase Agreement with C/M when needed.

Our ability to use the